Navigation Links
Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ)
Date:7/28/2010

BOCA RATON, Fla., July 28 /PRNewswire/ -- Breckenridge announced today that through its agreement with Tris Pharma, the company will market Methylphenidate Solution, the generic version of Methylin® marketed by Shionogi Pharma, Inc., under an Abbreviated New Drug Application (ANDA).  Under the terms of this agreement, the products will be manufactured by Tris Pharma, and marketed and distributed by Breckenridge on an exclusive basis in the U.S.  The companies plan to start shipping immediately. Methylphenidate Oral Solution was filed with a Paragraph IV Certification under Hatch-Waxman and, having "first-to-file status," the companies will enjoy a 180-Day generic exclusivity period granted under the statute. Separately the two companies also have an agreement to market several additional ANDA liquids upon approval by the FDA.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of Generic prescription products in many therapeutic categories; including several unique ValuBrand™ products. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, including multiple ANDA's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. Breckenridge was recently honored as a 50th Anniversary DIANA award winner for "Best Overall Generic Products Manufacturer" by the HDMA in October 2009.

www.bpirx.com

About Tris Pharma:

Tris Pharma is a privately owned, product-focused, specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release technology in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' NoBuse™ platform provides abuse-deterrence for opioids and other abuse-prone drugs. The company has more than 20 Rx and OTC products in development with pharmaceutical partners. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey.

www.trispharma.com

Methylin is a registered trademark of Mallinckrodt Inc.


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Approval of Anastrozole Tablets
2. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
5. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
6. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
7. Foundation Venture Capital Group Sells Interest in Longevica Pharmaceuticals
8. Colorcon Acquires Business of Pharmaceutical Coatings Pvt. Ltd. (India)
9. Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
11. Health Outcomes Data Essential to Biopharmaceutical Sales Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... COTTONWOOD HEIGHTS, Utah , Feb. 8, 2016 ... manufacturer and distributor of advanced-technology medical devices and ... and related markets, congratulates the Denver Broncos, football ... Kelvyn H. Cullimore Jr. , Chairman and ... tradition of excellence and we look forward to ...
(Date:2/8/2016)... Feb. 8, 2016 Palatin Technologies, Inc. ... receptor-specific peptide therapeutics for the treatment of diseases ... announced today that the United States Patent and ... Allowance for U.S. Patent Application Serial Number 14/313,258 ... methods of treating female sexual dysfunction using the ...
(Date:2/8/2016)... HOUSTON , 8. Februar 2016 /PRNewswire/ ... veröffentlichte heute eine Infografik mit dem Titel ... ganzen Welt), mit der der Krankheit gegenüber ... die dazu ermutigen soll, Medikamentenresistenz bei Epilepsie ... der allgemeinen Diskussion zu machen. Mithilfe der ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 2016 , ... Coast Dental has a new way to help parents keep ... family dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, February 19 ... Target at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will have healthy ...
(Date:2/8/2016)... ... 08, 2016 , ... If you are feeling that your clothes are a ... According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult ... types of cancer, some of the leading causes of preventable death. February is ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s ... booths and 700 companies. Attendees also get to see the most incredible gardens ... & Home Show , at the Colorado Convention Center - 700 14th St. Denver ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi ... and 11th, 2016 in honor of his birthday on February 10th. During this ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries as ...
Breaking Medicine News(10 mins):